Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00114049 · ClinicalTrials.gov registry record · Phase 3
Dental Pain (Following Third Molar Tooth Extraction) Study
A Phase 3 study of Dental Pain and Surgery, Dental, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 3
- Development phase
- 300
- Enrollment target
- 1
- Study location
NCT00114049 is a Phase 3 study of Dental Pain and Surgery, Dental that has completed, run by GlaxoSmithKline. The registered enrollment target is 300 participants, above the 195-participant average among 6 other Dental Pain trials with a reported enrollment target (54% higher). The trial reports 1 study location across 1 state.
The verdict
NCT00114049, a Phase 3 study of Dental Pain and Surgery, Dental, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 300 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to evaluate the effectiveness of GW406381 (a COX-2 inhibitor) in treating the signs and symptoms of dental pain following third molar tooth extraction.
Conditions Studied
Interventions
- DRUG GW406381
Study Locations (1)
Texas
- GSK Investigational Site - Austin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2004-12 |
| Est. Completion | 2005-04 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00114049
The ClinicalTrials.gov registry entry for NCT00114049 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 300 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 195-participant average among 6 other Dental Pain trials with a reported enrollment target (54% higher). The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Dental Pain appearing as the primary indexed condition, and to 1 intervention - of which GW406381 is the first listed.
NCT00114049 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT00114049 about?
NCT00114049 is a clinical study titled "Dental Pain (Following Third Molar Tooth Extraction) Study". The purpose of this study is to evaluate the effectiveness of GW406381 (a COX-2 inhibitor) in treating the signs and symptoms of dental pain following third molar tooth extraction.
What is the current status of trial NCT00114049?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 300 participants. The study started on 2004-12. Estimated completion is 2005-04.
What conditions does trial NCT00114049 study?
This clinical trial studies the following conditions: Dental Pain, Surgery, Dental.
What interventions are being tested in trial NCT00114049?
The interventions under investigation include: GW406381 (DRUG).
Who is sponsoring clinical trial NCT00114049?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00114049 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Dental Pain
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Evaluation of EXPAREL for Prolonged Postsurgical Analgesia in Subjects Undergoing Third Molar Extraction
COMPLETED · Phase 3
-
Exploration of the Utility of Dental-dedicated MRI for Dentistry
RECRUITING
-
Photobiomodulation and Tooth Analgesia
RECRUITING · NA
-
Dental Block for Pain Relief in ED Dental Pain Patients
RECRUITING
-
A Study of ARRY-371797 in Subjects Undergoing Third Molar Extraction
COMPLETED · Phase 2
-
Safety and Efficacy Study of XPF-001 to Treat Pain Following Wisdom Tooth Extraction
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.